Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTCNASDAQ:CLLSNASDAQ:PHATNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$14.61-2.2%$14.42$6.66▼$17.15$383.51M0.4443,016 shs182,501 shsCLLSCellectis$1.47+5.0%$1.48$1.10▼$2.43$81.71M2.92143,257 shs77,868 shsPHATPhathom Pharmaceuticals$10.42-4.4%$5.23$2.21▼$19.71$727.46M0.081.51 million shs1.83 million shsRGNXREGENXBIO$8.43-1.6%$8.75$5.04▼$15.36$422.85M1.09925,983 shs2.55 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma0.00%-11.35%+7.51%-9.31%+101.52%CLLSCellectis0.00%+10.53%-5.47%+13.08%-27.05%PHATPhathom Pharmaceuticals0.00%-2.07%+146.34%+67.26%-12.22%RGNXREGENXBIO0.00%-9.06%-14.50%+2.31%-30.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.5151 of 5 stars3.62.00.00.02.92.50.0CLLSCellectis3.3792 of 5 stars3.55.00.00.02.32.50.6PHATPhathom Pharmaceuticals3.8258 of 5 stars4.52.00.00.01.95.00.6RGNXREGENXBIO4.4085 of 5 stars3.42.00.04.63.23.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.22Buy$23.8363.13% UpsideCLLSCellectis 3.00Buy$4.00172.11% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5067.95% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63275.15% UpsideCurrent Analyst Ratings BreakdownLatest CLLS, PHAT, RGNX, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/9/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/2/2025PHATPhathom PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.005/2/2025PHATPhathom PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $12.005/2/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $20.004/21/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K4,793.91N/AN/A$4.68 per share3.12CLLSCellectis$49.22M1.66N/AN/A$2.36 per share0.62PHATPhathom Pharmaceuticals$55.25M13.17N/AN/A($3.71) per share-2.81RGNXREGENXBIO$83.33M5.07N/AN/A$5.24 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-38.26%-35.71%N/ACLLSCellectis-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)Latest CLLS, PHAT, RGNX, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec Biopharma0.0114.8014.80CLLSCellectis0.441.671.67PHATPhathom PharmaceuticalsN/A3.583.54RGNXREGENXBION/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%CLLSCellectis63.90%PHATPhathom Pharmaceuticals99.01%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%CLLSCellectis16.41%PHATPhathom Pharmaceuticals23.00%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataCLLSCellectis29055.58 million46.46 millionOptionablePHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionableRGNXREGENXBIO37050.16 million43.75 millionOptionableCLLS, PHAT, RGNX, and BNTC HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 16, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?June 11, 2025 | marketbeat.comA Glimpse Into The Expert Outlook On Regenxbio Through 8 AnalystsJune 9, 2025 | benzinga.comREGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan CapitalJune 9, 2025 | marketbeat.comRegenxbio's RGX-121 Could Become The New Standard Of Care In Hunter SyndromeJune 6, 2025 | seekingalpha.comOtsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne updateJune 6, 2025 | biopharmadive.comRegeNXBio shares fall, despite positive new data on RGX-202June 6, 2025 | thepharmaletter.comRegenxbio’s Duchenne gene therapy data positive as shares falterJune 5, 2025 | bioworld.comRegenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene TherapyJune 5, 2025 | biospace.comREGENXBIO updates Phase 1/2 data for Duchenne candidateJune 5, 2025 | msn.comEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerJune 5, 2025 | benzinga.comREGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202June 5, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 5, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?June 3, 2025 | marketbeat.comShort Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%June 3, 2025 | marketbeat.comBank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)June 3, 2025 | marketbeat.comREGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202June 2, 2025 | prnewswire.comTwo Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1, 2025 | marketbeat.comTwo Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)June 1, 2025 | marketbeat.comFY2026 EPS Estimates for REGENXBIO Increased by AnalystMay 31, 2025 | marketbeat.comMillennium Management LLC Buys 1,061,187 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLLS, PHAT, RGNX, and BNTC Company DescriptionsBenitec Biopharma NASDAQ:BNTC$14.61 -0.33 (-2.21%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$14.56 -0.05 (-0.38%) As of 06/20/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Cellectis NASDAQ:CLLS$1.47 +0.07 (+5.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.44 -0.02 (-1.70%) As of 06/20/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Phathom Pharmaceuticals NASDAQ:PHAT$10.42 -0.48 (-4.40%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$10.50 +0.07 (+0.72%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.REGENXBIO NASDAQ:RGNX$8.43 -0.14 (-1.63%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.52 +0.09 (+1.01%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
